Press Releases Kyowa Kirin Co. Ltd.

Equities

4151

JP3256000005

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-09 EDT			5-day change	1st Jan Change
2,644 ^JPY	+0.38%		-0.86%	+11.58%

05-07	Kyowa Kirin's Profit Up 15% in Q1	MT
05-06	Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kyowa Kirin : Transcript of Results Briefing Fiscal 2024 First Quarter (0B)	08:37am	PU
Kyowa Kirin : Results Presentation Fiscal 2024 First Quarter (0B)	05-07	PU
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	05-06	AQ
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ (istradefylline) and Other Parkinson's Disease Add-On Therapies	04-15	AQ
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome	04-15	BU
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024	03-11	AQ
Kyowa Kirin : Partial Corrections to “Notice of Convocation of the 101st Ordinary General Meeting of Shareholders” (0B)	03-05	PU
Kyowa Kirin Co., Ltd - Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc	01-26	AQ
Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases	01-24	BU
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases	01-24	AQ
Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others	12-07	AQ
Kyowa Kirin : Transcript of Results Presentation Fiscal 2023 Third Quarter (text) (0B)	11-06	PU
Kyowa Kirin : Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (0B)	11-01	PU
Kyowa Kirin : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (0B)	11-01	PU
Kyowa Kirin : Results Presentation Fiscal 2023 Third Quarter (0B)	11-01	PU
Kyowa Kirin : Announces Presentations of the Results of Phase 3 Studies of PHOZEVEL® for Patients with Hyperphosphatemia Undergoing Dialysis in Japan at the American Society of Nephrology Meeting (291KB)	23-10-17	PU
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023	23-10-11	AQ
Kyowa Kirin to Acquire Orchard Therapeutics	23-10-05	AQ
Kyowa Kirin : Announces Approval for Partial Change of Rituximab Biosimilar Received by Sandoz in Japan (316KB)	23-09-29	PU
Kyowa Kirin : Announces Approval of PHOZEVEL® for Improvement of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis in Japan (296KB)	23-09-25	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kyowa Kirin Co. Ltd.

Equities

4151

JP3256000005

Press Releases

Filters